Samsung BioLogics wins deal to produce CytoDyn's drug candidate leronlimab

[Yonhap Photo]

SEOUL -- Samsung BioLogics, a leading bio company in South Korea, has won a commission product contract from CytoDyn, an American biotech company, to produce its flagship drug candidate, leronlimab, which is at the final stage of clinical trial as a once-weekly monotherapy for HIV-infected patients.

Samsung BioLogics said Tuesday that the deal worth $31 million could grow up to $246 million by 2027 if commercial production begins. CytoDyn has applied for fast-track designation by the Food and Drug Administration (FDA).

The American company has said that a preclinical study of leronlimab showed a 98 percent reduction of breast cancer tumor metastasis after seven weeks. The target of leronlimab is a cellular receptor that appears to play multiple roles with implications in HIV infection, tumor metastases and immune signaling.

In January, Samsung Bioepis, a joint venture between Samsung BioLogics and U.S.-based pharmaceutical company Biogen, won FDA approval to sell Ontruzant, a cancer-treating biosimilar referencing Herceptin.

Lim Chang-won cwlim34@ajunews.com

Samsung BioLogics wins deal to produce CytoDyn's drug candidate leronlimab

Related

Hyodol to showcase AI-powered companion robot at MWC in Barcelona

AI care robot 'Hyodol' registered as medical device in US

VUNO's AI brain image analysis solution wins US health department's approval as medical device